Browse EPS15L1

Summary
SymbolEPS15L1
Nameepidermal growth factor receptor pathway substrate 15-like 1
Aliases eps15R; epidermal growth factor receptor substrate EPS15R; eps15-related protein; Epidermal growth factor re ......
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Peripheral membrane protein Nucleus Membrane, coated pit Note=Localized to plasma membrane coated pits.
Domain PF12763 Cytoskeletal-regulatory complex EF hand
Function

Seems to be a constitutive component of clathrin-coated pits that is required for receptor-mediated endocytosis. Involved in endocytosis of integrin beta-1 (ITGB1) and transferrin receptor (TFR); internalization of ITGB1 as DAB2-dependent cargo but not TFR seems to require association with DAB2.

> Gene Ontology
 
Biological Process GO:0007173 epidermal growth factor receptor signaling pathway
GO:0038127 ERBB signaling pathway
GO:0042058 regulation of epidermal growth factor receptor signaling pathway
GO:0042059 negative regulation of epidermal growth factor receptor signaling pathway
GO:1901184 regulation of ERBB signaling pathway
GO:1901185 negative regulation of ERBB signaling pathway
Molecular Function GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005905 clathrin-coated pit
GO:0005913 cell-cell adherens junction
GO:0030117 membrane coat
GO:0030118 clathrin coat
GO:0030132 clathrin coat of coated pit
GO:0048475 coated membrane
GO:0098589 membrane region
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
Reactome R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-182971: EGFR downregulation
R-HSA-199991: Membrane Trafficking
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolEPS15L1
Nameepidermal growth factor receptor pathway substrate 15-like 1
Aliases eps15R; epidermal growth factor receptor substrate EPS15R; eps15-related protein; Epidermal growth factor re ......
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EPS15L1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolEPS15L1
Nameepidermal growth factor receptor pathway substrate 15-like 1
Aliases eps15R; epidermal growth factor receptor substrate EPS15R; eps15-related protein; Epidermal growth factor re ......
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EPS15L1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.89 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolEPS15L1
Nameepidermal growth factor receptor pathway substrate 15-like 1
Aliases eps15R; epidermal growth factor receptor substrate EPS15R; eps15-related protein; Epidermal growth factor re ......
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EPS15L1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0040.983
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0690.968
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0560.965
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0030.99
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1180.956
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1450.959
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0520.859
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1590.91
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0660.966
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.380.734
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6210.713
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0080.852
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EPS15L1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.118.8-7.71
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEPS15L1
Nameepidermal growth factor receptor pathway substrate 15-like 1
Aliases eps15R; epidermal growth factor receptor substrate EPS15R; eps15-related protein; Epidermal growth factor re ......
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EPS15L1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEPS15L1
Nameepidermal growth factor receptor pathway substrate 15-like 1
Aliases eps15R; epidermal growth factor receptor substrate EPS15R; eps15-related protein; Epidermal growth factor re ......
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EPS15L1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EPS15L1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEPS15L1
Nameepidermal growth factor receptor pathway substrate 15-like 1
Aliases eps15R; epidermal growth factor receptor substrate EPS15R; eps15-related protein; Epidermal growth factor re ......
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EPS15L1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEPS15L1
Nameepidermal growth factor receptor pathway substrate 15-like 1
Aliases eps15R; epidermal growth factor receptor substrate EPS15R; eps15-related protein; Epidermal growth factor re ......
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EPS15L1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEPS15L1
Nameepidermal growth factor receptor pathway substrate 15-like 1
Aliases eps15R; epidermal growth factor receptor substrate EPS15R; eps15-related protein; Epidermal growth factor re ......
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EPS15L1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEPS15L1
Nameepidermal growth factor receptor pathway substrate 15-like 1
Aliases eps15R; epidermal growth factor receptor substrate EPS15R; eps15-related protein; Epidermal growth factor re ......
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EPS15L1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.